--- title: "Conveglipron | PepTracker Pro" url: https://peptrackerpro.com/peptides/conveglipron description: "An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Conveglipron Low Evidence An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron. Aliases HDM1002 +4 more Evidence Low Evidence Last Updated 2026-07-15 Reading Time 3 min ## What It Is Conveglipron (developmental code HDM1002) is an investigational oral, once-daily small molecule that activates the GLP-1 receptor, being developed by China-based Huadong Medicine for obesity and type 2 diabetes. Unlike injectable GLP-1 peptides such as semaglutide and tirzepatide, conveglipron is a small-molecule full agonist of the GLP-1 receptor designed to be taken as a pill, placing it in the same emerging class as Eli Lilly's orforglipron and the discontinued Pfizer candidate danuglipron. The appeal of an oral GLP-1 is convenience and scalability: pills are easier to manufacture, distribute, and store at scale than injectable peptides, and they avoid needles. In a published first-in-human single-ascending-dose study (Diabetes, Obesity & Metabolism, 2025) and a randomized, double-blind, placebo-controlled multiple-ascending-dose Phase 1b study in Chinese adults with overweight or obesity (Obesity, 2026), conveglipron was generally well tolerated over 28 days of dosing and produced dose-dependent weight loss, with participants in the higher dose groups losing roughly 4.9% to 6.8% of body weight by day 28. The most common side effects were gastrointestinal — mostly mild nausea and vomiting — consistent with the GLP-1 drug class. As of early 2026, conveglipron was reported to be in Phase 3 trials for type 2 diabetes and Phase 2 trials for obesity in China. It is investigational, is not approved by the FDA or, for obesity, by any regulator, and is not a marketed, prescribed, or compounded consumer product. Despite acting at the same receptor as GLP-1 peptides, conveglipron is a small molecule, not a peptide. Also known as: HDM1002, HDM-1002, conveglipron (HDM1002), oral GLP-1 small molecule, Huadong oral GLP-1 ## Why Researchers Study It Conveglipron targets one of obesity and diabetes medicine's biggest practical goals: delivering GLP-1 efficacy in a low-cost, scalable oral small molecule rather than an injectable peptide. Researchers are interested in whether an oral small-molecule GLP-1 agonist can approach the weight loss and glucose control of injectable GLP-1 drugs while remaining tolerable, and how it stacks up against the leading oral GLP-1 candidate orforglipron. Because pills can be manufactured far more cheaply and at greater volume than peptides, a successful oral GLP-1 could dramatically expand global access — making conveglipron part of a closely watched race to define the next generation of obesity therapeutics beyond the injectable era. ## Proposed Mechanisms - Acts as a selective, potent small-molecule full agonist of the GLP-1 receptor - Stimulates glucose-dependent insulin secretion to improve blood-sugar control - Promotes satiety and reduces food intake through central GLP-1 signaling - Slows gastric emptying to prolong post-meal fullness - Designed for oral, once-daily dosing rather than injection ## Evidence Snapshot Low Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Human (Phase 1b, randomized placebo-controlled) | Multiple-ascending-dose study in 60 Chinese adults with overweight/obesity, 50–400 mg over 28 days | Generally well tolerated; dose-dependent weight loss with higher-dose groups losing ~4.9%–6.8% of body weight by day 28; adverse events mostly mild gastrointestinal (nausea, vomiting) | Source: https://onlinelibrary.wiley.com/doi/10.1002/oby.70160 | | Human (Phase 1, first-in-human single-ascending-dose) | Escalating single oral doses in healthy volunteers | Acceptable safety, tolerability, and pharmacokinetic/pharmacodynamic profile supporting further development | Source: https://doi.org/10.1111/dom.16610 | ## Commonly Discussed Benefits Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Researching Conveglipron? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=conveglipron) ## Safety & Cautions - Investigational and not approved by the FDA; not approved for obesity by any regulator (reported Phase 2 for obesity, Phase 3 for type 2 diabetes in China as of early 2026) - Not a marketed, prescribed, or compounded consumer product — anything sold online under this name should be treated with extreme caution - It is a small molecule, not a peptide, despite acting at the same GLP-1 receptor as semaglutide and tirzepatide - Published human data are short-term (28 days); long-term efficacy, durability, and safety are not established - Causes dose-dependent gastrointestinal side effects (nausea, vomiting) typical of GLP-1 drugs - Most published clinical data come from trials in China; broader populations and long-term outcomes remain to be studied ## Comparisons See how Conveglipron compares to related peptides: Conveglipron vs ACCG-2671: https://peptrackerpro.com/compare/conveglipron-vs-accg-2671 Conveglipron vs Aleniglipron: https://peptrackerpro.com/compare/conveglipron-vs-aleniglipron Conveglipron vs CX11: https://peptrackerpro.com/compare/conveglipron-vs-cx11 Conveglipron vs Danuglipron: https://peptrackerpro.com/compare/conveglipron-vs-danuglipron Conveglipron vs Ecnoglutide: https://peptrackerpro.com/compare/conveglipron-vs-ecnoglutide Conveglipron vs Elecoglipron: https://peptrackerpro.com/compare/conveglipron-vs-elecoglipron Conveglipron vs KAI-7535: https://peptrackerpro.com/compare/conveglipron-vs-kai-7535 Conveglipron vs Orforglipron: https://peptrackerpro.com/compare/conveglipron-vs-orforglipron Conveglipron vs Semaglutide: https://peptrackerpro.com/compare/conveglipron-vs-semaglutide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Xu et al. — HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo-Controlled, Ascending-Dose Phase 1b Study (Obesity, 2026) PubMed (https://onlinelibrary.wiley.com/doi/10.1002/oby.70160) 2. [2] Pu J. et al. — First-in-human study of HDM1002, a GLP-1 receptor agonist: single-dose safety, tolerability, PK and PD in healthy volunteers (Diabetes, Obesity & Metabolism, 2025) PubMed (https://doi.org/10.1111/dom.16610) 3. [3] Huadong Medicine — Positive Phase I Results for Oral Small Molecule GLP-1 Receptor Agonist HDM1002 (PR Newswire) PubMed (https://www.prnewswire.com/news-releases/huadong-medicine-announces-positive-phase-i-results-for-innovative-oral-small-molecule-glp-1-receptor-agonist-hdm1002-302183199.html) ### Keep researching in the app - Log Conveglipron to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=conveglipron Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### ACCG-2671 Low Evidence An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection. View Details: https://peptrackerpro.com/peptides/accg-2671 \+ Compare: https://peptrackerpro.com/compare?select=accg-2671 Track in App: https://app.peptrackerpro.com/?add=accg-2671 ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/aleniglipron \+ Compare: https://peptrackerpro.com/compare?select=aleniglipron Track in App: https://app.peptrackerpro.com/?add=aleniglipron ### CX11 Medium Evidence CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/cx11 \+ Compare: https://peptrackerpro.com/compare?select=cx11 Track in App: https://app.peptrackerpro.com/?add=cx11 ### Danuglipron Medium Evidence An oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/danuglipron \+ Compare: https://peptrackerpro.com/compare?select=danuglipron Track in App: https://app.peptrackerpro.com/?add=danuglipron ### Ecnoglutide High Evidence A cAMP signaling-biased GLP-1 receptor agonist approved in China for chronic weight management, with Phase 3 data showing up to 15.4% weight loss. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/ecnoglutide \+ Compare: https://peptrackerpro.com/compare?select=ecnoglutide Track in App: https://app.peptrackerpro.com/?add=ecnoglutide ### Elecoglipron Medium Evidence An investigational, once-daily oral small-molecule GLP-1 receptor agonist from AstraZeneca that delivered up to about 11.8% weight loss at 36 weeks in people with obesity or overweight and strong blood-sugar control in type 2 diabetes, and is now advancing into a large Phase 3 program. Unlike semaglutide and tirzepatide - which are injectable peptides - elecoglipron is a small chemical molecule that mimics the natural GLP-1 hormone at its receptor in the gut and hypothalamus, so it can be taken as a pill with no food or fasting restrictions and is easier and cheaper to manufacture at global scale than peptide drugs. In the Phase 2b VISTA trial (n=310) the 75 mg once-daily regimen produced an average body-weight reduction of 10.5% at 26 weeks (vs 0.6% placebo) that had not plateaued, reaching about 11.8% at 36 weeks, with up to 88.8% of participants achieving at least 5% weight loss. In the Phase 2b SOLSTICE trial in type 2 diabetes (n=404) the 75 mg regimen cut HbA1c by 1.9% at 26 weeks (vs 0.2% placebo) - with roughly 90% of participants reaching an HbA1c below 7% - alongside 7.7% weight loss, numerically ahead of an open-label oral semaglutide 14 mg comparator arm. Side effects were the familiar GLP-1 class gastrointestinal symptoms (nausea, constipation, diarrhea, vomiting), mostly mild to moderate, with infrequent discontinuations and no liver safety signals. Both trials were presented at the 2026 American Diabetes Association (ADA) Scientific Sessions in New Orleans and published simultaneously in The Lancet, and on June 8, 2026 AstraZeneca announced elecoglipron would move into an extensive Phase 3 program - the EMBOLD obesity trials and the ELUMINATE type 2 diabetes trials (including combination with dapagliflozin), plus cardiovascular and kidney outcome studies. Elecoglipron is an investigational prescription-stage medicine - it is not approved anywhere and is not a supplement or research chemical. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Glycemic Control (https://peptrackerpro.com/benefits/glycemic-control)+1 more View Details: https://peptrackerpro.com/peptides/elecoglipron \+ Compare: https://peptrackerpro.com/compare?select=elecoglipron Track in App: https://app.peptrackerpro.com/?add=elecoglipron ### KAI-7535 Medium Evidence An oral once-daily small-molecule GLP-1 receptor agonist (Hengrui's HRS-7535, licensed to Kailera) that delivered up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and met its Phase 3 diabetes endpoint, now in a global Phase 2 dose-optimization study. View Details: https://peptrackerpro.com/peptides/kai-7535 \+ Compare: https://peptrackerpro.com/compare?select=kai-7535 Track in App: https://app.peptrackerpro.com/?add=kai-7535 ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. View Details: https://peptrackerpro.com/peptides/orforglipron \+ Compare: https://peptrackerpro.com/compare?select=orforglipron Track in App: https://app.peptrackerpro.com/?add=orforglipron ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Conveglipron", "description": "An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron.", "url": "https://peptrackerpro.com/peptides/conveglipron", "lastReviewed": "2026-07-15", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Conveglipron", "item": "https://peptrackerpro.com/peptides/conveglipron" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following the race to develop an oral (pill) GLP-1 drug for weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Conveglipron is a research peptide studied in preclinical models. An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron." } }, { "@type": "Question", "name": "Those comparing oral GLP-1 candidates such as orforglipron, danuglipron, and conveglipron?", "acceptedAnswer": { "@type": "Answer", "text": "Conveglipron is a research peptide studied in preclinical models. An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron." } }, { "@type": "Question", "name": "Researchers and investors tracking Huadong Medicine's metabolic pipeline?", "acceptedAnswer": { "@type": "Answer", "text": "Conveglipron is a research peptide studied in preclinical models. An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron." } }, { "@type": "Question", "name": "People asking whether there is an oral alternative to injectable GLP-1 therapies like semaglutide?", "acceptedAnswer": { "@type": "Answer", "text": "Conveglipron is a research peptide studied in preclinical models. An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron." } } ] } ] ```